Area riservata
CRF icona.org
Contatti
2022
- Greenberg L, Ryom L, Neesgaard B, Miró JM, Dahlerup Rasmussen L, Zangerle R, Grabmeier-Pfistershammer K, Günthard HF, Kusejko K, Smith C, Mussini C, Menozzi M, Wit F, Van Der Valk M, d'Arminio Monforte A, De Wit S, Necsoi C, Pelchen-Matthews A, Lundgren J, Peters L, Castagna A, Muccini C, Vehreschild JJ, Pradier C, Bruguera Riera A, Sönnerborg A, Petoumenos K, Garges H, Rogatto F, Dedes N, Bansi-Matharu L, Mocroft A; RESPOND Study Group. Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting. Open Forum Infect Dis. 2022;9(3):ofac029
- Byonanebye DM, Polizzotto MN, Neesgaard B, Sarcletti M, Matulionyte R, Braun DL, Castagna A, de Wit S, Wit F, Fontas E, Vehreschild JJ, Vesterbacka J, Greenberg L, Hatleberg C, Garges H, Gallant J, Volny Anne A, Öllinger A, Mozer-Lisewska I, Surial B, Spagnuolo V, Necsoi C, van der Valk M, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. HIV Med. 2022. Epub ahead of print
- Neesgaard B, Greenberg L, Miró JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C, De Wit S, Wit F, Pelchen-Matthews A, Mussini C, Castagna A, Pradier C, d'Arminio Monforte A, Vehreschild JJ, Sönnerborg A, Anne AV, Carr A, Bansi-Matharu L, Lundgren JD, Garges H, Rogatto F, Zangerle R, Günthard HF, Rasmussen LD, Necsoi C, van der Valk M, Menozzi M, Muccini C, Peters L, Mocroft A, Ryom L. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium Lancet HIV. 2022:S2352-3018(22)00094-7
- Jaschinski N, Greenberg L, Neesgaard B, Miró JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C, De Wit S, Wit F, Pelchen-Matthews A, Mussini C, Castagna A, Pradier C, Monforte A, Vehreschild J, Sönnerborg A, Anne AV, Carr A, Bansi-Matharu L, Lundgren J, Garges H, Rogatto F, Zangerle R, Günthard HF, Rasmussen LD, Nescoi C, Van Der Valk M, Menozzi M, Muccini C, Mocroft A, Peters L, Ryom L; RESPOND Study Group. Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV. AIDS. 2022. Epub ahead of print
2021
- Byonanebye DM; RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS 2021
- Bansi-Matharu L, Phillips A, Oprea C, Grabmeier-Pfistershammer K, Günthard HF, De Wit S, Guaraldi G, Vehreschild JJ, Wit F, Law M, Wasmuth JC, Chkhartishvili N, d'Arminio Monforte A, Fontas E, Vesterbacka J, Miro JM, Castagna A, Stephan C, Llibre JM, Neesgaard B, Greenberg L, Smith C, Kirk O, Duvivier C, Dragovic G, Lundgren J, Dedes N, Knudsen A, Gallant J, Vannappagari V, Peters L, Elbirt D, Sarcletti M, Braun DL, Necsoi C, Mussini C, Muccini C, Bolokadze N, Hoy J, Mocroft A, Ryom L. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium. Lancet HIV. 2021:S2352-3018(21)00163-6. Epub ahead of print.
2020
- Bastian Neesgaard, Amanda Mocroft, Robert Zangerle, Ferdinand Wit, Fiona Lampe, Huldrych F Günthard, Coca Necsoi, Matthew Law, Cristina Mussini, Antonella Castagna, Antonella d'Arminio Monforte, Christian Pradier, Nikoloz Chkhartisvilli, Juliana Reyes-Uruena, Jörg Janne Vehreschild, Jan-Christian Wasmuth, Anders Sönnerborg, Christoph Stephan, Lauren Greenberg, Josep M Llibre, Alain Volny-Anne, Lars Peters, Annegret Pelchen-Matthews, Vani Vannappagari, Joel Gallant, Armin Rieger, Mike Youle, Dominique Braun, Stephane De Wit, Kathy Petoumenos, Vanni Borghi, Vincenzo Spagnuolo, Tengiz Tsertsvadze, Jens Lundgren, Lene Ryom, RESPOND study group Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS One . 2020;15(12):e0243625
- Greenberg L, Ryom L, Neesgaard B, Wandeler G, Staub T, Gisinger M, Skoll M, Günthard HF, Scherrer A, Mussini C, Smith C, Johnson M, De Wit S, Necsoi C, Pradier C, Wit F, Lehmann C, d'Arminio Monforte A, Miró JM, Castagna A, Spagnuolo V, Sönnerborg A, Law M, Hutchinson J, Chkhartishvili N, Bolokadze N, Wasmuth JC, Stephan C, Vannappagari V, Rogatto F, Llibre JM, Duvivier C, Hoy J, Bloch M, Bucher HC, Calmy A, Volny Anne A, Pelchen-Matthews A, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND study group. Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV. Clin Infect Dis. 2020
- RESPOND Study Group, Ryom, L., Peters, L. & Lundgren, J. D. The interrelationship of smoking, CD4+ cell count, viral load and cancer in persons living with HIV. AIDS. 2020;35(5):747-757.
- B Neesgaard, A Mocroft, L Greenberg, JF Larsen, G Wandeler, R Zangerle, H Günthard, C Smith, S De Wit, C Mussini, A Castagna, a D'Arminio Monforte, JJ Vehreschild, JC Wasmuth, C Pradier, N Chkhartishvili, F W.N.M. Wit, M Law, A Sönnerborg, A Bruguera, C Stephan, V Vannappagari, R Haubrich, O Kirk, D Podlekareva, J Kowalska, D Raben, J Rockstroh, L Peters, R Parades, K Grabmeier-Pfistershammer, A Scherrer, M Johnson, C Necsoi, V Borghi, C Muccini, T Tserstvadze, K Petoumenos, A Volny-Anne, J Lundgren, L Ryom, for the RESPOND study group How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium. Microorganisms. 2020;8(8):E1164
- Mocroft, A, and RESPOND study group Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment. HIV Med. 2020
- Greenberg L, Ryom L, Wandeler G, Grabmeier-Pfistershammer K, Öllinger A, Neesgaard B, Stephan C, Calmy A, Rauch A, Castagna A, Spagnuolo V, Johnson M, Stingone C, Mussini C, De Wit S, Necsoi C, Campins AA, Pradier C, Stecher M, Wasmuth JC, Monforte AD, Law M, Puhr R, Chkhartishvilli N, Tsertsvadze T, Garges H, Thorpe D, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND Study Group Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting J Acquir Immune Defic Syndr. 2020;83(3):240-250
